GSK-3 as potential target for therapeutic intervention in cancer

The serine/threonine kinase glycogen synthase kinase-3 (GSK-3) was initially identified and studied in the regulation of glycogen synthesis. GSK-3 functions in a wide range of cellular processes. Aberrant activity of GSK-3 has been implicated in many human pathologies including: bipolar depression, Alzheimer's disease, Parkinson's disease, cancer, non-insulin-dependent diabetes mellitus (NIDDM) and others. In some cases, suppression of GSK-3 activity by phosphorylation by Akt and other kinases has been associated with cancer progression. In these cases, GSK-3 has tumor suppressor functions. In other cases, GSK-3 has been associated with tumor progression by stabilizing components of the beta-catenin complex. In these situations, GSK-3 has oncogenic properties. While many inhibitors to GSK-3 have been developed, their use remains controversial because of the ambiguous role of GSK-3 in cancer development. In this review, we will focus on the diverse roles that GSK-3 plays in various human cancers, in particular in solid tumors. Recently, GSK-3 has also been implicated in the generation of cancer stem cells in various cell types. We will also discuss how this pivotal kinase interacts with multiple signaling pathways such as: PI3K/PTEN/Akt/mTORC1, Ras/Raf/MEK/ERK, Wnt/beta-catenin, Hedgehog, Notch and others.

[1]  S. Morrison,et al.  mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion. , 2010, Cell stem cell.

[2]  Christian Hölscher,et al.  GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease , 2012, Reviews in the neurosciences.

[3]  A. Xu,et al.  Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. , 2006, Cancer research.

[4]  N. Kay,et al.  Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. , 2007, Blood.

[5]  J. Curtin,et al.  Drug Discovery Approaches to Target Wnt Signaling in Cancer Stem Cells , 2010, Oncotarget.

[6]  M. Hung,et al.  Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Anne-Claude Gingras,et al.  Wilms Tumor Suppressor WTX Negatively Regulates WNT/ß-Catenin Signaling , 2007, Science.

[8]  Mark J. Murphy,et al.  Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy , 2008, Nature.

[9]  F. McCormick,et al.  Differential Regulation of Glycogen Synthase Kinase 3β by Insulin and Wnt Signaling* , 2000, The Journal of Biological Chemistry.

[10]  J. Feliu,et al.  β-Catenin expression pattern in primary oesophageal squamous cell carcinoma. Relationship with clinicopathologic features and clinical outcome , 2000, Virchows Archiv.

[11]  Hilla Peretz,et al.  Ju n 20 03 Schrödinger ’ s Cat : The rules of engagement , 2003 .

[12]  A. G. Herreros,et al.  The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumour cells , 2000, Nature Cell Biology.

[13]  Matthias Mann,et al.  Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. , 2002, Genes & development.

[14]  F. Marincola,et al.  A human memory T-cell subset with stem cell-like properties , 2011, Nature Medicine.

[15]  Dianqing Wu,et al.  GSK3: a multifaceted kinase in Wnt signaling. , 2010, Trends in biochemical sciences.

[16]  Stephen L. Abrams,et al.  Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway , 2011, Leukemia.

[17]  G. Visani,et al.  Haematological effects of lithium carbonate: a study in 56 psychiatric patients. , 1981, Haematologica.

[18]  Jun Qin,et al.  Erk Associates with and Primes GSK-3β for Its Inactivation Resulting in Upregulation of β-Catenin , 2005 .

[19]  R. Joyce.  Sequential effects of lithium on haematopoiesis , 1984, British journal of haematology.

[20]  Christof Niehrs,et al.  Casein kinase 1 gamma couples Wnt receptor activation to cytoplasmic signal transduction. , 2005, Nature.

[21]  J. Lieberman,et al.  Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. , 2010, Trends in pharmacological sciences.

[22]  H. Clevers,et al.  LKB1 and AMPK family signaling: the intimate link between cell polarity and energy metabolism. , 2009, Physiological reviews.

[23]  G. Mills,et al.  Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[24]  B. Gajkowska,et al.  Alzheimer's disease genetic mutation evokes ultrastructural alterations: correlation to an intracellular Abeta deposition and the level of GSK-3beta-P(Y216) phosphorylated form. , 2009, Neurotoxicology.

[25]  O. Pourquié,et al.  Notch signalling is required for cyclic expression of the hairy-like gene HES1 in the presomitic mesoderm. , 2000, Development.

[26]  Stephen L. Abrams,et al.  Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells , 2011, Cell cycle.

[27]  Y. Yura,et al.  Mutations of the APC, beta-catenin, and axin 1 genes and cytoplasmic accumulation of beta-catenin in oral squamous cell carcinoma , 2005, Journal of Cancer Research and Clinical Oncology.

[28]  M. Hung,et al.  Degradation of Mcl-1 by β-TrCP Mediates Glycogen Synthase Kinase 3-Induced Tumor Suppression and Chemosensitization , 2006, Molecular and Cellular Biology.

[29]  J. Bartek,et al.  Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. , 1995, Cancer letters.

[30]  L. Espinosa,et al.  Phosphorylation by Glycogen Synthase Kinase-3β Down-regulates Notch Activity, a Link for Notch and Wnt Pathways* , 2003, Journal of Biological Chemistry.

[31]  Rosa Bernardi,et al.  PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. , 2006, Nature.

[32]  Hans Clevers,et al.  Wnt/β-Catenin Signaling and Disease , 2012, Cell.

[33]  L. Larsson,et al.  c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. , 2000, Blood.

[34]  K. Rajewsky,et al.  Burkitt lymphomagenesis linked to MYC plus PI3K in germinal center B cells , 2012, Oncotarget.

[35]  I. Grundke‐Iqbal,et al.  Role of protein phosphatase‐2A and ‐1 in the regulation of GSK‐3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain , 2000, FEBS letters.

[36]  Bin Zhang,et al.  Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. , 2005, Biochemical and biophysical research communications.

[37]  N. Kim,et al.  MiRNA-34 intrinsically links p53 tumor suppressor and Wnt signaling , 2012, Cell cycle.

[38]  Anna-Pavlina G. Haramis,et al.  Insights from model organisms on the functions of the tumor suppressor protein LKB1: Zebrafish chips in , 2011, Aging.

[39]  F. D. de Sauvage,et al.  Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. , 2011, Cancer research.

[40]  Ming You,et al.  TSC2 Integrates Wnt and Energy Signals via a Coordinated Phosphorylation by AMPK and GSK3 to Regulate Cell Growth , 2006, Cell.

[41]  M. Hung,et al.  β-Catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression , 2000 .

[42]  K. Kang,et al.  Troglitazone, a PPAR agonist, inhibits human prostate cancer cell growth through inactivation of NFκB via suppression of GSK-3β expression , 2011, Cancer biology & therapy.

[43]  Yee‐Shin Lin,et al.  Increased galectin-3 facilitates leukemia cell survival from apoptotic stimuli. , 2011, Biochemical and biophysical research communications.

[44]  Maria M. Mihaylova,et al.  AMPK and PPARδ Agonists Are Exercise Mimetics , 2008, Cell.

[45]  S. Dalton,et al.  Reconciling the different roles of Gsk3β in “naïve” and “primed” pluripotent stem cells , 2012, Cell cycle.

[46]  J. Blenis,et al.  Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation , 2011, Proceedings of the National Academy of Sciences.

[47]  Stephen L. Abrams,et al.  Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine , 2012, Cell cycle.

[48]  A. Nakashima,et al.  Specific Activation of mTORC1 by Rheb G-protein in Vitro Involves Enhanced Recruitment of Its Substrate Protein* , 2009, Journal of Biological Chemistry.

[49]  Xin Lu,et al.  Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. , 2006, Cell research.

[50]  Weiguo Lu,et al.  Overexpression of Glycogen Synthase Kinase-3 in Ovarian Carcinoma Cells With Acquired Paclitaxel Resistance , 2010, International Journal of Gynecologic Cancer.

[51]  A. Kimmel,et al.  Receptor-dependent and tyrosine phosphatase-mediated inhibition of GSK3 regulates cell fate choice. , 2002, Developmental cell.

[52]  P. Cohen,et al.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B , 1995, Nature.

[53]  S. Cagnol,et al.  Inhibition of glycogen synthase kinase-3 activity triggers an apoptotic response in pancreatic cancer cells through JNK-dependent mechanisms. , 2012, Carcinogenesis.

[54]  Xin Lu,et al.  Glycogen synthase kinase-3β positively regulates the proliferation of human ovarian cancer cells , 2006, Cell Research.

[55]  A. Sharma.  Molecular Cellular Biology , 2011 .

[56]  C. Montagna,et al.  Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors , 2011, Oncotarget.

[57]  C. Brenner,et al.  Faculty Opinions recommendation of AMPK and PPARdelta agonists are exercise mimetics. , 2008 .

[58]  R. Arceci.  PML targeting eradicates quiescent leukaemia-initiating cells , 2009 .

[59]  Stephen L. Abrams,et al.  Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response , 2012, Oncotarget.

[60]  D. Sabatini,et al.  DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival , 2009, Cell.

[61]  A. Reith,et al.  The structure of phosphorylated GSK-3beta complexed with a peptide, FRATtide, that inhibits beta-catenin phosphorylation. , 2001, Structure.

[62]  L. Chin,et al.  LKB1 regulates quiescence and metabolic homeostasis of hematopoietic stem cells , 2010, Nature.

[63]  P. S. Klein,et al.  Maintenance of Hematopoietic Stem Cells through Regulation of Wnt and mTOR Pathways , 2012, Nature Medicine.

[64]  Xi He,et al.  A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation , 2005, Nature.

[65]  D. Krause,et al.  Mammalian Suppressor-of-Fused modulates nuclear–cytoplasmic shuttling of GLI-1 , 1999, Nature Cell Biology.

[66]  R. Cardiff,et al.  Protein kinase CK2: Signaling and tumorigenesis in the mammary gland , 2001, Molecular and Cellular Biochemistry.

[67]  C. Emerson,et al.  Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[68]  F. Costantini,et al.  Impaired mammary gland and lymphoid development caused by inducible expression of Axin in transgenic mice , 2001, The Journal of cell biology.

[69]  Stephen L. Abrams,et al.  Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention , 2013, Leukemia.

[70]  J. Gutkind,et al.  Faculty Opinions recommendation of Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation. , 2008 .

[71]  K. Flaherty,et al.  An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. , 2007, Cancer research.

[72]  J. Woodgett,et al.  Molecular cloning and expression of glycogen synthase kinase‐3/factor A. , 1990, The EMBO journal.

[73]  R. DePinho,et al.  mTORC1 signaling governs hematopoietic stem cell quiescence , 2009, Cell cycle.

[74]  Hans van Dam,et al.  GSK3β inactivation induces apoptosis of leukemia cells by repressing the function of c-Myb , 2011, Molecular biology of the cell.

[75]  G. Genovese,et al.  The tumor suppressor HINT1 regulates MITF and β-catenin transcriptional activity in melanoma cells , 2012, Cell cycle.

[76]  T. Dale,et al.  The Regulation of Glycogen Synthase Kinase-3 Nuclear Export by Frat/GBP* , 2002, The Journal of Biological Chemistry.

[77]  Huei-Sheng Huang,et al.  Involvement of glycogen synthase kinase-3β in arsenic trioxide-induced p21 expression. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[78]  B. Jiang,et al.  Glycogen synthase kinase-3 beta regulates Snail and β-catenin expression during Fas-induced epithelial-mesenchymal transition in gastrointestinal cancer. , 2013, European journal of cancer.

[79]  T. Curran,et al.  The Hedgehog's tale: developing strategies for targeting cancer , 2011, Nature Reviews Cancer.

[80]  C. Klebanoff,et al.  Pharmacologic Induction of CD8+ T Cell Memory: Better Living Through Chemistry , 2009, Science Translational Medicine.

[81]  Eun-Mi Hur,et al.  GSK3 signalling in neural development , 2010, Nature Reviews Neuroscience.

[82]  R. Craig,et al.  Thr 163 Phosphorylation Causes Mcl-1 Stabilization when Degradation Is Independent of the Adjacent GSK3-Targeted Phosphodegron, Promoting Drug Resistance in Cancer , 2012, PloS one.

[83]  Sean E. Egan,et al.  Elevated PI3K signaling drives multiple Breast Cancer subtypes , 2011, Oncotarget.

[84]  P. Greengard,et al.  GSK-3-selective inhibitors derived from Tyrian purple indirubins. , 2003, Chemistry & biology.

[85]  C. Desbois-Mouthon,et al.  Glycogen synthase kinase-3 inhibitors augment TRAIL-induced apoptotic death in human hepatoma cells. , 2009, Biochemical pharmacology.

[86]  J. Clapham,et al.  Thermogenic and metabolic antiobesity drugs: rationale and opportunities , 2007, Diabetes, obesity & metabolism.

[87]  S. Howng,et al.  GSK3beta regulates Bcl2L12 and Bcl2L12A anti‐apoptosis signaling in glioblastoma and is inhibited by LiCl , 2012, Cell cycle.

[88]  Rosa Bernardi,et al.  PML inhibits HIF-1α translation and neoangiogenesis through repression of mTOR , 2006, Nature.

[89]  J. Bartek,et al.  Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. , 1994, Cancer research.

[90]  Rajakishore Mishra.  Glycogen synthase kinase 3 beta: can it be a target for oral cancer , 2010, Molecular Cancer.

[91]  E. Lam,et al.  Role of glycogen synthase kinase 3 beta (GSK3β) in mediating the cytotoxic effects of the histone deacetylase inhibitor trichostatin A (TSA) in MCF-7 breast cancer cells , 2006, Molecular Cancer.

[92]  V. Bilim,et al.  GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC). , 2012, Biochemical and biophysical research communications.

[93]  Jun Qin,et al.  Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. , 2005, Molecular cell.

[94]  Stephen Bartlett,et al.  Involvement of GSK-3 in regulation of murine embryonic stem cell self-renewal revealed by a series of bisindolylmaleimides. , 2009, Chemistry & biology.

[95]  B. Martín-Castillo,et al.  Metformin activates an Ataxia Telangiectasia Mutated (ATM)/Chk2-regulated DNA damage-like response , 2011, Cell cycle.

[96]  A. Ougolkov,et al.  Inhibition of glycogen synthase kinase-3. , 2008, Methods in molecular biology.

[97]  Alexander J. Valvezan,et al.  Adenomatous Polyposis Coli (APC) Regulates Multiple Signaling Pathways by Enhancing Glycogen Synthase Kinase-3 (GSK-3) Activity* , 2011, The Journal of Biological Chemistry.

[98]  Xi He,et al.  Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. , 2002, Cell.

[99]  R. Fodde,et al.  Wnt/Β-Catenin and Sex Hormone Signaling In Endometrial Homeostasis and Cancer , 2010, Oncotarget.

[100]  Stephen L. Abrams,et al.  Cooperative Effects of Akt-1 and Raf-1 on the Induction of Cellular Senescence in Doxorubicin or Tamoxifen Treated Breast Cancer Cells , 2011, Oncotarget.

[101]  P. Cohen,et al.  Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. , 1980, European journal of biochemistry.

[102]  Raphael Kopan,et al.  Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain , 1998, Nature.

[103]  F. Hofmann,et al.  Inhibition of IGF-I receptor in anchorage-independence attenuates GSK-3β constitutive phosphorylation and compromises growth and survival of medulloblastoma cell lines , 2007, Oncogene.

[104]  Stephen L. Abrams,et al.  Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging , 2011, Aging.

[105]  I. Shin,et al.  Glycogen synthase kinase 3-β phosphorylates novel S/T-P-S/T domains in Notch1 intracellular domain and induces its nuclear localization. , 2012, Biochemical and biophysical research communications.

[106]  P. Vogt,et al.  Phosphorylation of AKT: a Mutational Analysis , 2011, Oncotarget.

[107]  R. Howland.  Lithium: underappreciated and underused? , 2007, Journal of psychosocial nursing and mental health services.

[108]  Yukihiro Matsuda,et al.  Casein kinase I phosphorylates the Armadillo protein and induces its degradation in Drosophila , 2002, The EMBO journal.

[109]  A. Dar,et al.  t-Darpp promotes cancer cell survival by up-regulation of Bcl2 through Akt-dependent mechanism. , 2008, Cancer research.

[110]  M. Menon,et al.  Anticancer efficacy of deguelin in human prostate cancer cells targeting glycogen synthase kinase‐3 β/β‐catenin pathway , 2011, International journal of cancer.

[111]  J. Burger,et al.  Phosphoinositide 3′-kinase delta: turning off BCR signaling in Chronic Lymphocytic Leukemia , 2011, Oncotarget.

[112]  E. Robertis,et al.  Integrating Patterning Signals: Wnt/GSK3 Regulates the Duration of the BMP/Smad1 Signal , 2007, Cell.

[113]  J. Backer,et al.  A beta version of life: p110β takes center stage , 2010, Oncotarget.

[114]  K. Kawakami,et al.  Deregulated GSK3 Sustains Gastrointestinal Cancer Cells Survival by Modulating Human Telomerase Reverse Transcriptase and Telomerase , 2009, Clinical Cancer Research.

[115]  Donald Wolfgeher,et al.  GSK-3 Promotes Cell Survival, Growth, and PAX3 Levels in Human Melanoma Cells , 2012, Molecular Cancer Research.

[116]  P. Cohen,et al.  The mechanism by which epidermal growth factor inhibits glycogen synthase kinase 3 in A431 cells. , 1994, The Biochemical journal.

[117]  M. Carter,et al.  The Development of New Therapeutics for Alzheimer's Disease , 2010, Clinical pharmacology and therapeutics.

[118]  D. Dinh,et al.  Cord blood stem cells revert glioma stem cell EMT by down regulating transcriptional activation of Sox2 and Twist1 , 2011, Oncotarget.

[119]  A. Yoshimura,et al.  Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3beta. , 2004, Genes & development.

[120]  Xi He,et al.  Control of β-Catenin Phosphorylation/Degradation by a Dual-Kinase Mechanism , 2002, Cell.

[121]  J. Woodgett,et al.  Glycogen synthase kinase-3 and cancer: good cop, bad cop? , 2008, Cancer cell.

[122]  G. Johnson,et al.  Glycogen Synthase Kinase 3β Is Tyrosine Phosphorylated by PYK2 , 2001 .

[123]  R. Jope,et al.  Insulin Transiently Increases Tau Phosphorylation , 1999, Journal of neurochemistry.

[124]  E. Morrisey,et al.  Wnt and Kras signaling-dark siblings in lung cancer , 2011, Oncotarget.

[125]  J. McCubrey,et al.  AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications , 2012, Leukemia.

[126]  J. Woodgett,et al.  Modulation of the glycogen synthase kinase‐3 family by tyrosine phosphorylation. , 1993, The EMBO journal.

[127]  P. Park,et al.  The Lkb1 metabolic sensor maintains haematopoietic stem cell survival , 2011, Nature.

[128]  宮下 勝吉.  Potential therapeutic effect of glycogen synthase kinase 3β inhibition against human glioblastoma , 2009 .

[129]  D. Spandidos,et al.  Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). , 2011, International journal of oncology.

[130]  P. Cohen,et al.  A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. , 2001, Molecular Cell.

[131]  James R. Woodgett,et al.  Lithium inhibits glycogen synthase kinase-3 activity and mimics Wingless signalling in intact cells , 1996, Current Biology.

[132]  Gustavo Pedraza-Alva,et al.  Phosphorylation by p38 MAPK as an Alternative Pathway for GSK3β Inactivation , 2008, Science.

[133]  S. Lomvardas,et al.  A GSK3β Phosphorylation Site in Axin Modulates Interaction with β-Catenin and Tcf-Mediated Gene Expression , 1999 .

[134]  A. Reith,et al.  The Structure of Phosphorylated GSK-3β Complexed with a Peptide, FRATtide, that Inhibits β-Catenin Phosphorylation , 2001 .

[135]  Danica Chen,et al.  The sirtuins, oxidative stress and aging: an emerging link , 2013, Aging.

[136]  C. Klebanoff,et al.  Paths to stemness: building the ultimate antitumour T cell , 2012, Nature Reviews Cancer.

[137]  A. Pérez-Castillo,et al.  Inhibition of Glioblastoma Growth by the Thiadiazolidinone Compound TDZD-8 , 2010, PloS one.

[138]  Carlos A. Garcia,et al.  Convergence of the Mammalian Target of Rapamycin Complex 1- and Glycogen Synthase Kinase 3-β–Signaling Pathways Regulates the Innate Inflammatory Response , 2011, The Journal of Immunology.

[139]  C. Arteaga,et al.  Will PI3K pathway inhibitors be effective as single agents in patients with cancer? , 2011, Oncotarget.

[140]  Michael Kühl,et al.  The ankyrin repeat protein Diversin recruits Casein kinase Iepsilon to the beta-catenin degradation complex and acts in both canonical Wnt and Wnt/JNK signaling. , 2002, Genes & development.

[141]  O. Ilkayeva,et al.  Glycogen synthase kinase 3alpha and 3beta mediate a glucose-sensitive antiapoptotic signaling pathway to stabilize Mcl-1. , 2007, Molecular and cellular biology.

[142]  P. Pandolfi,et al.  Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. , 2008, The Journal of clinical investigation.

[143]  A. Wynshaw-Boris,et al.  Wnt signaling in mammalian development: lessons from mouse genetics. , 2012, Cold Spring Harbor perspectives in biology.

[144]  S. Lomvardas,et al.  A GSK3beta phosphorylation site in axin modulates interaction with beta-catenin and Tcf-mediated gene expression. , 1999, Biochemical and biophysical research communications.

[145]  S. Weiss,et al.  A Wnt–Axin2–GSK3β cascade regulates Snail1 activity in breast cancer cells , 2006, Nature Cell Biology.

[146]  G. Struhl,et al.  Nuclear Access and Action of Notch In Vivo , 1998, Cell.

[147]  M. MacCoss,et al.  Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. , 2007, Science.

[148]  Daniel R. Foltz,et al.  Glycogen Synthase Kinase-3β Modulates Notch Signaling and Stability , 2002, Current Biology.

[149]  Jieun Song,et al.  Down‐regulation of Notch‐dependent transcription by Akt in vitro , 2008, FEBS letters.

[150]  Chiou-Feng Lin,et al.  Anesthetic Propofol Causes Glycogen Synthase Kinase-3&bgr;-regulated Lysosomal/Mitochondrial Apoptosis in Macrophages , 2012, Anesthesiology.

[151]  Xinming Cai,et al.  Glycogen Synthase Kinase 3- and Extracellular Signal-Regulated Kinase-Dependent Phosphorylation of Paxillin Regulates Cytoskeletal Rearrangement , 2006, Molecular and Cellular Biology.

[152]  B. Doble,et al.  Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines. , 2007, Developmental cell.

[153]  A. Reith,et al.  Expression and Characterization of GSK-3 Mutants and Their Effect on β-Catenin Phosphorylation in Intact Cells* , 2002, The Journal of Biological Chemistry.

[154]  H. Miki,et al.  Sufu recruits GSK3beta for efficient processing of Gli3. , 2009, Biochemical and biophysical research communications.

[155]  S. Maggirwar,et al.  Glycogen Synthase Kinase 3β-Mediated Apoptosis of Primary Cortical Astrocytes Involves Inhibition of Nuclear Factor κB Signaling , 2003, Molecular and Cellular Biology.

[156]  Herb Chen,et al.  Inactivation of glycogen synthase kinase-3β, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells , 2007, Molecular Cancer Therapeutics.

[157]  W. Tong,et al.  Pivotal role for glycogen synthase kinase-3 in hematopoietic stem cell homeostasis in mice. , 2009, The Journal of clinical investigation.

[158]  K. Kawakami,et al.  Aberrant Glycogen Synthase Kinase 3β Is Involved in Pancreatic Cancer Cell Invasion and Resistance to Therapy , 2013, PloS one.

[159]  Michael Martin,et al.  Glycogen synthase kinase 3: a point of convergence for the host inflammatory response. , 2011, Cytokine.

[160]  W. Snider,et al.  Evidence that glycogen synthase kinase‐3 isoforms have distinct substrate preference in the brain , 2010, Journal of neurochemistry.

[161]  P. Fletcher,et al.  Abnormalities in brain structure and behavior in GSK-3alpha mutant mice , 2009, Molecular Brain.

[162]  O. Forlenza,et al.  Does Lithium Prevent Alzheimer’s Disease? , 2012, Drugs & Aging.

[163]  L. Popplewell,et al.  β‐catenin as a potential key target for tumor suppression , 2011, International journal of cancer.

[164]  R. Urrutia,et al.  Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. , 2005, Cancer research.

[165]  J. McCubrey,et al.  Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells , 2014, Cell cycle.

[166]  Taosheng Chen,et al.  Glycogen synthase kinase 3 regulates PAX3-FKHR-mediated cell proliferation in human alveolar rhabdomyosarcoma cells. , 2010, Biochemical and biophysical research communications.

[167]  H. Bae,et al.  Antidiabetic effect of propolis: reduction of expression of glucose‐6‐phosphatase through inhibition of Y279 and Y216 autophosphorylation of GSK‐3α/β in HepG2 cells , 2010, Phytotherapy research : PTR.

[168]  B. Doble,et al.  GSK-3: tricks of the trade for a multi-tasking kinase , 2003, Journal of Cell Science.

[169]  Tian-Li Wang,et al.  Jagged1 Expression Regulated by Notch3 and Wnt/β-catenin Signaling Pathways in Ovarian Cancer , 2010, Oncotarget.

[170]  B. Ponsioen,et al.  GSK-3 is activated by the tyrosine kinase Pyk2 during LPA1-mediated neurite retraction. , 2006, Molecular biology of the cell.

[171]  M. Roussel,et al.  Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. , 1998, Genes & development.

[172]  R. Urrutia,et al.  Glycogen Synthase Kinase-3β Participates in Nuclear Factor κB–Mediated Gene Transcription and Cell Survival in Pancreatic Cancer Cells , 2005 .

[173]  William J. Ray,et al.  A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain , 1999, Nature.

[174]  A. Thor,et al.  Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions , 2011, Cell cycle.

[175]  D. M. Ferkey,et al.  Glycogen Synthase Kinase-3β Mutagenesis Identifies a Common Binding Domain for GBP and Axin* , 2002, The Journal of Biological Chemistry.

[176]  D. Scadden,et al.  The hematopoietic stem cell in its place , 2006, Nature Immunology.

[177]  P. Pandolfi,et al.  Pml represses tumour progression through inhibition of mTOR , 2011, EMBO molecular medicine.

[178]  J. Woodgett,et al.  Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation , 2000, Nature.

[179]  Christopher A. Maher,et al.  A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial–mesenchymal transition , 2011, The Journal of cell biology.

[180]  P. Sirota,et al.  Increased number of peripheral blood CD34+ cells in lithium‐treated patients , 1998, British journal of haematology.

[181]  W. Zhou,et al.  ShRNA silencing glycogen synthase kinase-3 beta inhibits tumor growth and angiogenesis in pancreatic cancer. , 2012, Cancer letters.

[182]  Jan-Gowth Chang,et al.  Correlation between protein expression and epigenetic and mutation changes of Wnt pathway-related genes in oral cancer. , 2003, International journal of oncology.

[183]  Yang Liu,et al.  mTOR Regulation and Therapeutic Rejuvenation of Aging Hematopoietic Stem Cells , 2009, Science Signaling.

[184]  A. Yoshimura,et al.  Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3β , 2004 .

[185]  K. Nakayama,et al.  Phosphorylation‐dependent degradation of c‐Myc is mediated by the F‐box protein Fbw7 , 2004, The EMBO journal.

[186]  P. Cohen,et al.  Glycogen synthase kinase-3 from rabbit skeletal muscle. , 2005, Methods in enzymology.

[187]  P. Polakis,et al.  Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. , 1996, Science.

[188]  P. Cohen,et al.  Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. , 1993, The Biochemical journal.

[189]  R. Moon,et al.  Regulating the response to targeted MEK inhibition in melanoma , 2012, Cell cycle.

[190]  K. Cassidy,et al.  Pharmacokinetics, Metabolism, and Excretion of the Glycogen Synthase Kinase-3 Inhibitor LY2090314 in Rats, Dogs, and Humans: A Case Study in Rapid Clearance by Extensive Metabolism with Low Circulating Metabolite Exposure , 2013, Drug Metabolism and Disposition.

[191]  C. W. Scott,et al.  Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[192]  D. Melton,et al.  A molecular mechanism for the effect of lithium on development. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[193]  B. Doble,et al.  Glycogen synthase kinase-3--an overview of an over-achieving protein kinase. , 2006, Current drug targets.

[194]  Austin G Smith,et al.  The ground state of pluripotency. , 2010, Biochemical Society transactions.

[195]  David J. Fleet,et al.  Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. , 2012, Journal of Alzheimer's disease : JAD.

[196]  Dianqing Wu,et al.  Suppression of Glycogen Synthase Kinase Activity Is Not Sufficient for Leukemia Enhancer Factor-1 Activation* , 1999, The Journal of Biological Chemistry.

[197]  R. Dolcetti,et al.  GSK-3b inhibition: At the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma , 2008 .

[198]  Shanshan Wang,et al.  Hepatitis B virus X protein promotes hepatoma cell invasion and metastasis by stabilizing Snail protein , 2012, Cancer science.

[199]  Hans Clevers,et al.  Wnt Signaling Controls the Phosphorylation Status of β-Catenin* , 2002, The Journal of Biological Chemistry.

[200]  Xi He,et al.  Wnt/beta-catenin signaling: components, mechanisms, and diseases. , 2009, Developmental cell.

[201]  J. Auwerx,et al.  Negative regulation of Jun/AP-1: conserved function of glycogen synthase kinase 3 and the Drosophila kinase shaggy. , 1993, Oncogene.

[202]  J. V. Vanden Heuvel,et al.  Modulation of PPAR activity via phosphorylation. , 2007, Biochimica et biophysica acta.

[203]  Adam Cole,et al.  Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. , 2004, The Biochemical journal.

[204]  J. McCubrey,et al.  Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies , 2012, Expert opinion on therapeutic targets.

[205]  T. Han,et al.  Cyclin G1–mediated epithelial‐mesenchymal transition via phosphoinositide 3‐kinase/Akt signaling facilitates liver cancer progression , 2012, Hepatology.

[206]  J. Feliu,et al.  beta-catenin expression pattern in primary oesophageal squamous cell carcinoma. Relationship with clinicopathologic features and clinical outcome. , 2000, Virchows Archiv : an international journal of pathology.

[207]  E. Goncharova,et al.  PI3K/mTORC1 activation in hamartoma syndromes: Therapeutic prospects , 2009, Cell cycle.

[208]  Yang Liu,et al.  TSC–mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species , 2008, The Journal of experimental medicine.

[209]  M. Ding,et al.  The role of glycogen synthase kinase 3beta in the transformation of epidermal cells. , 2007, Cancer research.

[210]  V. Palomo,et al.  The potential role of glycogen synthase kinase 3 inhibitors as amyotrophic lateral sclerosis pharmacological therapy. , 2011, Current medicinal chemistry.

[211]  K. Kawakami,et al.  Potential Therapeutic Effect of Glycogen Synthase Kinase 3β Inhibition against Human Glioblastoma , 2009, Clinical Cancer Research.

[212]  C. Desbois-Mouthon,et al.  Dysregulation of glycogen synthase kinase-3beta signaling in hepatocellular carcinoma cells. , 2002, Hepatology.

[213]  A. Aliaga,et al.  Metformin abolishes increased tumor 18F-2-fluoro-2-deoxy-D-glucose uptake associated with a high energy diet , 2011, Cell cycle.

[214]  J. Woodgett,et al.  Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. , 1994, The Biochemical journal.

[215]  Kirk W. Johnson,et al.  Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. , 2003, Diabetes.

[216]  Gabriela Alexe,et al.  The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia. , 2012, The Journal of clinical investigation.

[217]  Paul Polakis,et al.  Binding of GSK3β to the APC-β-Catenin Complex and Regulation of Complex Assembly , 1996, Science.

[218]  A. Dolnikov,et al.  Using small molecule GSK3β inhibitors to treat inflammation. , 2010, Current medicinal chemistry.

[219]  Antonio Vidal-Puig,et al.  Characterisation of the phosphorylation of beta-catenin at the GSK-3 priming site Ser45. , 2002, Biochemical and biophysical research communications.

[220]  T. He,et al.  Enhancement of Canonical Wnt/β-Catenin Signaling Activity by HCV Core Protein Promotes Cell Growth of Hepatocellular Carcinoma Cells , 2011, PloS one.

[221]  O. MacDougald,et al.  Glycogen Synthase Kinase 3 Is an Insulin-Regulated C/EBPα Kinase , 1999, Molecular and Cellular Biology.

[222]  Naping Li,et al.  Bleomycin-induced nuclear factor-kappaB activation in human bronchial epithelial cells involves the phosphorylation of glycogen synthase kinase 3beta. , 2009, Toxicology letters.

[223]  C. Sakanaka.  Phosphorylation and regulation of beta-catenin by casein kinase I epsilon. , 2002, Journal of biochemistry.

[224]  K. Mchugh,et al.  Snail Regulates Cell-Matrix Adhesion by Regulation of the Expression of Integrins and Basement Membrane Proteins* , 2008, Journal of Biological Chemistry.

[225]  A. Zeiher,et al.  Glycogen Synthase Kinase-3 Couples AKT-dependent Signaling to the Regulation of p21Cip1 Degradation* , 2002, The Journal of Biological Chemistry.

[226]  D. Rakus,et al.  Muscle FBPase binds to cardiomyocyte mitochondria under glycogen synthase kinase‐3 inhibition or elevation of cellular Ca2+ level , 2012, FEBS letters.

[227]  P. Pandolfi,et al.  A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance , 2012, Nature Medicine.

[228]  O. MacDougald,et al.  Glycogen synthase kinase 3 is an insulin-regulated C/EBPalpha kinase. , 1999, Molecular and cellular biology.

[229]  J. Woodgett,et al.  Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. , 2000, Nature.

[230]  T. Ohtsuka,et al.  Hes1 and Hes5 as Notch effectors in mammalian neuronal differentiation , 1999, The EMBO journal.

[231]  D. Xie,et al.  Maelstrom promotes hepatocellular carcinoma metastasis by inducing epithelial‐mesenchymal transition by way of Akt/GSK‐3β/Snail signaling , 2014, Hepatology.

[232]  S. Hellberg,et al.  AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans , 2013, Journal of neurochemistry.

[233]  Chika Yokota,et al.  Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions , 2007, Development.

[234]  Kwonseop Kim,et al.  Regulation of Notch1/NICD and Hes1 expressions by GSK-3α/β , 2009, Molecules and cells.

[235]  Hee-Sae Park,et al.  Beta-catenin modulates the level and transcriptional activity of Notch1/NICD through its direct interaction. , 2009, Biochimica et biophysica acta.

[236]  F. White,et al.  Mcl-1 Integrates the Opposing Actions of Signaling Pathways That Mediate Survival and Apoptosis , 2009, Molecular and Cellular Biology.

[237]  T. Shimura.  Acquired radioresistance of cancer and the AKT/GSK3β/cyclin D1 overexpression cycle. , 2011, Journal of radiation research.

[238]  G. Mills,et al.  Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. , 2005, Cancer research.

[239]  C. So,et al.  Selective treatment of mixed-lineage leukemia leukemic stem cells through targeting glycogen synthase kinase 3 and the canonical Wnt/&bgr;-catenin pathway , 2012, Current opinion in hematology.

[240]  F. Khuri,et al.  Maintaining glycogen synthase kinase-3 activity is critical for mTOR kinase inhibitors to inhibit cancer cell growth. , 2014, Cancer research.

[241]  K. Kawakami,et al.  An emerging strategy for cancer treatment targeting aberrant glycogen synthase kinase 3 beta. , 2009, Anti-cancer agents in medicinal chemistry.

[242]  B. Winblad,et al.  Interplay between glycogen synthase kinase‐3β and tau in the cerebellum of Hsp27 transgenic mouse , 2011, Journal of neuroscience research.

[243]  S. Bray.  Notch signalling: a simple pathway becomes complex , 2006, Nature Reviews Molecular Cell Biology.

[244]  S. Hanks,et al.  Regulation of FAK Ser-722 phosphorylation and kinase activity by GSK3 and PP1 during cell spreading and migration. , 2005, The Biochemical journal.

[245]  D. Hallahan,et al.  LABORATORY INVESTIGATION – HUMAN/ANIMAL TISSUE GSK-3b inhibition promotes cell death, apoptosis, and in vivo , 2022 .

[246]  Stephen L. Abrams,et al.  Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy , 2011, Oncotarget.

[247]  Hideki Yamamoto,et al.  Phosphorylation of Axin, a Wnt Signal Negative Regulator, by Glycogen Synthase Kinase-3β Regulates Its Stability* , 1999, The Journal of Biological Chemistry.

[248]  Ying Qi,et al.  Phosphorylation by Glycogen Synthase Kinase-3 Controls c-Myc Proteolysis and Subnuclear Localization* , 2003, Journal of Biological Chemistry.

[249]  S. Habib.  Mechanism of Activation of AMPK and Upregulation of OGG1 by Rapamycin in Cancer Cells , 2011, Oncotarget.

[250]  A. Kikuchi,et al.  Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. , 1998, The EMBO journal.

[251]  G. Cooper,et al.  A GSK-3-mediated transcriptional network maintains repression of immediate early genes in quiescent cells , 2011, Cell cycle.

[252]  J. McCubrey,et al.  A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia , 2012, Oncotarget.

[253]  Zev A. Binder,et al.  Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells , 2011, Oncotarget.

[254]  R. Cardiff,et al.  Kinase-inactive glycogen synthase kinase 3beta promotes Wnt signaling and mammary tumorigenesis. , 2005, Cancer research.

[255]  H. Miki,et al.  GSK3beta positively regulates Hedgehog signaling through Sufu in mammalian cells. , 2007, Biochemical and biophysical research communications.

[256]  I. Randen,et al.  Glycogen synthase kinase-3 (GSK-3) inhibition induces apoptosis in leukemic cells through mitochondria-dependent pathway. , 2012, Leukemia research.

[257]  J. Paramio,et al.  Expression, localization, and activity of glycogen synthase kinase 3β during mouse skin tumorigenesis , 2002, Molecular carcinogenesis.

[258]  P. Massion,et al.  Role of STRAP in regulating GSK3β function and Notch3 stabilization , 2011, Cell cycle.

[259]  T. Laessig,et al.  Glycogen Synthase Kinase-3β Phosphorylates Bax and Promotes Its Mitochondrial Localization during Neuronal Apoptosis , 2004, The Journal of Neuroscience.

[260]  B. Doble,et al.  Functional redundancy of GSK-3α and GSK-3β in wnt/β-catenin signaling shown by using an allelic series of embryonic stem cell lines , 2007 .

[261]  Zhiyong Wang,et al.  Hexokinase regulates Bax-mediated mitochondrial membrane injury following ischemic stress. , 2011, Kidney international.

[262]  Jiri Bartek,et al.  Cyclin D1 protein expression and function in human breast cancer , 1994, International journal of cancer.

[263]  Michael Kühl,et al.  The ankyrin repeat protein Diversin recruits Casein kinase Iε to the β-catenin degradation complex and acts in both canonical Wnt and Wnt/JNK signaling , 2002 .

[264]  J. Tamburini,et al.  Targeting translation in acute myeloid leukemia: A new paradigm for therapy? , 2009, Cell cycle.

[265]  Nam-Gyun Kim,et al.  p53 and MicroRNA-34 Are Suppressors of Canonical Wnt Signaling , 2011, Science Signaling.

[266]  E. Vieta,et al.  Molecular targets of lithium action , 2003, Acta Neuropsychiatrica.

[267]  F. Trepiccione,et al.  Lithium-induced nephrogenic diabetes insipidus: new clinical and experimental findings. , 2010, Journal of nephrology.

[268]  Jia Luo,et al.  Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. , 2009, Cancer letters.

[269]  C. Sutherland.  What Are the bona fide GSK3 Substrates? , 2011, International journal of Alzheimer's disease.

[270]  F. Wandosell,et al.  Deconstructing GSK-3: The Fine Regulation of Its Activity , 2011, International journal of Alzheimer's disease.

[271]  B. Doble,et al.  Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism. , 2007, Cell metabolism.

[272]  K. Kuter,et al.  Glycogen Synthase Kinase 3β and Its Phosphorylated Form (Y216) in the Paraquat-Induced Model of Parkinsonism , 2010, Neurotoxicity Research.

[273]  A. Pyle,et al.  Defining the Role of Wnt/β‐Catenin Signaling in the Survival, Proliferation, and Self‐Renewal of Human Embryonic Stem Cells , 2005, Stem cells.

[274]  W. Drevets,et al.  A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. , 2009, The Journal of clinical psychiatry.

[275]  A. Eychène,et al.  GSK-3-mediated phosphorylation enhances Maf-transforming activity. , 2007, Molecular cell.

[276]  G. Johnson,et al.  Glycogen synthase kinase 3beta is tyrosine phosphorylated by PYK2. , 2001, Biochemical and biophysical research communications.

[277]  G. Yoon,et al.  Roles of GSK3 in metabolic shift toward abnormal anabolism in cell senescence , 2010, Annals of the New York Academy of Sciences.

[278]  Akira Kikuchi,et al.  Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK‐3β and β‐catenin and promotes GSK‐3β‐dependent phosphorylation of β‐catenin , 1998 .

[279]  Yu Wang,et al.  DNA-dependent protein kinase catalytic subunit modulates the stability of c-Myc oncoprotein , 2008, Molecular Cancer.

[280]  Wenyi Wei,et al.  Mcl-1 Ubiquitination and Destruction , 2011, Oncotarget.

[281]  Agnieszka Bronisz,et al.  microRNA-451: A conditional switch controlling glioma cell proliferation and migration , 2010, Cell cycle.

[282]  S. Maggirwar,et al.  Glycogen synthase kinase 3beta-mediated apoptosis of primary cortical astrocytes involves inhibition of nuclear factor kappaB signaling. , 2003, Molecular and cellular biology.

[283]  J. McCubrey,et al.  Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels , 2012, Oncotarget.

[284]  R. Jope,et al.  Proapoptotic Stimuli Induce Nuclear Accumulation of Glycogen Synthase Kinase-3β* , 2001, The Journal of Biological Chemistry.

[285]  J. Woodgett,et al.  Targeting GSK-3 family members in the heart: a very sharp double-edged sword. , 2011, Journal of molecular and cellular cardiology.

[286]  Christof Niehrs,et al.  Casein kinase 1 γ couples Wnt receptor activation to cytoplasmic signal transduction , 2005, Nature.

[287]  E. Liu,et al.  Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells. , 2005, Cancer research.

[288]  J. McCubrey,et al.  Targeted therapy for hepatocellular carcinoma: novel agents on the horizon , 2012, Oncotarget.

[289]  M. Atkins,et al.  GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. , 2008, The Journal of biological chemistry.

[290]  M. Ittmann,et al.  INPP4B: the New Kid on the PI3K Block , 2011, Oncotarget.

[291]  Barry P. Young,et al.  The Mck1 GSK-3 kinase inhibits the activity of Clb2-Cdk1 post-nuclear division , 2012, Cell cycle.

[292]  E. Henriksen.  Dysregulation of glycogen synthase kinase-3 in skeletal muscle and the etiology of insulin resistance and type 2 diabetes. , 2010, Current diabetes reviews.

[293]  R. Baiocchi,et al.  Novel targeted therapies for mantle cell lymphoma , 2012, Oncotarget.

[294]  C. Charvet,et al.  GSK-3 turns p53 deadly , 2011, Cell cycle.

[295]  P. S. Klein,et al.  Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. , 1997, Developmental biology.

[296]  Maqbool Ahmed,et al.  Regulation of myeloma cell growth through Akt/Gsk3/forkhead signaling pathway. , 2002, Biochemical and biophysical research communications.

[297]  M. Welham,et al.  Controlling embryonic stem cell proliferation and pluripotency: the role of PI3K- and GSK-3-dependent signalling. , 2011, Biochemical Society transactions.

[298]  D. Boggs,et al.  The hematopoietic effects of lithium. , 1983, Seminars in hematology.

[299]  Anirban Datta,et al.  Polarity proteins PAR6 and aPKC regulate cell death through GSK-3β in 3D epithelial morphogenesis , 2007, Journal of Cell Science.

[300]  S. Morrison,et al.  Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells , 2006, Nature.

[301]  L. Trentin,et al.  Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death , 2010, BMC Cancer.

[302]  K. Kawakami,et al.  Inhibition of GSK‐3β activity attenuates proliferation of human colon cancer cells in rodents , 2007, Cancer science.

[303]  Juan Chen,et al.  SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase‐3β/β‐catenin signaling , 2013, Hepatology.

[304]  U. Andersson,et al.  GSK-3 inhibition by an orally active small molecule increases bone mass in rats. , 2012, Bone.

[305]  James M. Roberts,et al.  Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. , 2003, Molecular cell.

[306]  A. Saltiel,et al.  The Activation of Glycogen Synthase by Insulin Switches from Kinase Inhibition to Phosphatase Activation during Adipogenesis in 3T3-L1 Cells* , 1998, The Journal of Biological Chemistry.

[307]  R. Dolcetti,et al.  GSK-3beta inhibition: at the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma. , 2008, Cell cycle.

[308]  Ge Zhang,et al.  Epithelial–Mesenchymal Transition (EMT) Induced by TNF-α Requires AKT/GSK-3β-Mediated Stabilization of Snail in Colorectal Cancer , 2013, PloS one.

[309]  R. Belmaker,et al.  The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases. , 2011, Current pharmaceutical design.

[310]  Sejeong Shin,et al.  Glycogen synthase kinase (GSK)-3 and mammalian target of rapamycin complex 1 (mTORC1) cooperate to regulate protein S6 kinase 1 (S6K1) , 2012, Cell cycle.

[311]  K. Kawakami,et al.  Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling. , 2013, Carcinogenesis.

[312]  P. Greengard,et al.  Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor , 2004, Nature Medicine.

[313]  O. Ilkayeva,et al.  Glycogen Synthase Kinase 3α and 3β Mediate a Glucose-Sensitive Antiapoptotic Signaling Pathway To Stabilize Mcl-1 , 2007, Molecular and Cellular Biology.

[314]  R. Moon,et al.  WNT signalling pathways as therapeutic targets in cancer , 2012, Nature Reviews Cancer.

[315]  L. Penn,et al.  The myc oncogene: MarvelouslY Complex. , 2002, Advances in cancer research.

[316]  Yagamare Fall,et al.  QSAR, docking, and CoMFA studies of GSK3 inhibitors. , 2010, Current pharmaceutical design.

[317]  Yong-Jun Jiang,et al.  Structural basis for the complete loss of GSK3β catalytic activity due to R96 mutation investigated by molecular dynamics study , 2009, Proteins.

[318]  B. Martín-Castillo,et al.  Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: Induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181a , 2011, Cell cycle.

[319]  M. Atkins,et al.  GSK-3β Inhibition Enhances Sorafenib-induced Apoptosis in Melanoma Cell Lines* , 2008, Journal of Biological Chemistry.

[320]  H. Herbst,et al.  Human telomerase reverse transcriptase (hTERT) is a target gene of β-catenin in human colorectal tumors , 2012, Cell cycle.

[321]  Y. Y. Koh,et al.  Generation of Multipotential Mesendodermal Progenitors from Mouse Embryonic Stem Cells via Sustained Wnt Pathway Activation*♦ , 2007, Journal of Biological Chemistry.